ALK inhibitor shows high response rate in patients with advanced NSCLC harboring a specific gene alteration

Bookmark and Share
Published: 11 Jun 2010
Views: 10019
Rating:
Save
Prof Yung-Jue Bang - Seoul National University College of Medicine, Seoul, Korea
Prof Yung-Jue Bang, speaking at the 2010 ASCO conference: A study featured in an ASCO plenary session shows that the majority of patients with advanced adenocarcinoma of the lung with a specific re-arrangement of the ALK gene responded to treatment with the investigational drug crizotinib (PF-02341066), which targets that genetic defect in the cancer cell. An estimated 5 percent of lung cancer patients have this ALK gene alteration.